Active Biotech’s Tasquinimod Shows Promise in Multiple Myeloma Study

Active Biotech AB ( (SE:ACTI) ) has provided an announcement.

Active Biotech announced the results of a study on tasquinimod, a drug candidate for relapsed refractory multiple myeloma, presented at the ASCO 2025 meeting. The study showed a 47% Clinical Benefit Rate in heavily pretreated patients, indicating potential synergistic efficacy when combined with standard therapies. These findings highlight tasquinimod’s potential to enhance the effectiveness of existing myeloma treatments and its tolerability aligns with previous studies, suggesting a promising future for its application in hematological malignancies.

More about Active Biotech AB

Active Biotech AB is a biotechnology company focused on developing first-in-class immunomodulatory treatments for oncology and immunology indications. The company has three projects in its portfolio, including tasquinimod and laquinimod, which are small molecule immunomodulators. Active Biotech is particularly focused on developing tasquinimod for myelofibrosis, a rare blood cancer, and is conducting clinical studies in multiple myeloma and non-infectious uveitis.

YTD Price Performance: 95.37%

Average Trading Volume: 29,591,760

Current Market Cap: SEK260.2M

Find detailed analytics on ACTI stock on TipRanks’ Stock Analysis page.